Blokhin A V, Yoo H D, Geralds R S, Nagle D G, Gerwick W H, Hamel E
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Mol Pharmacol. 1995 Sep;48(3):523-31.
Curacin A, the major lipid constituent of a strain of the marine cyanobacterium Lyngbya majuscula obtained off the coast of Curaçao, is a potent antimitotic agent that we have previously shown to inhibit microtubule assembly and colchicine binding to tubulin. In the present study, we report that curacin A probably binds in the colchicine site because it competitively inhibits the binding of [3H]colchicine to tubulin with an apparent Ki value of 0.6 microM and stimulates tubulin-dependent GTP hydrolysis, as do most other colchicine-site agents. The binding of curacin A to tubulin resembled the binding reactions of combretastatin A-4 and podophyllotoxin in contrast to that of colchicine in that it occurred as extensively on ice as at higher temperatures. However, once bound, the dissociation rate of curacin A from tubulin is very slow, more closely resembling that observed with colchicinoids (thiocolchicine was the drug examined) than the faster dissociation that occurs with combretastatin A-4 and podophyllotoxin. Because the molecular structure of curacin A is so different from that of previously described colchicine-site drugs (e.g., there is no aromatic moiety, and there are only two conjugated double bonds in its linear hydrocarbon chain), we have been examining the activities of natural isomers and synthetic derivatives. So far, only modest enhancement or reduction of activity has been observed with a variety of structural changes.
库拉索霉素A是从库拉索岛海岸采集的一种海洋蓝藻——巨大鞘丝藻菌株中的主要脂质成分,它是一种有效的抗有丝分裂剂,我们之前已证明它能抑制微管组装以及秋水仙碱与微管蛋白的结合。在本研究中,我们报告称库拉索霉素A可能结合在秋水仙碱结合位点,因为它能竞争性抑制[³H]秋水仙碱与微管蛋白的结合,其表观Ki值为0.6微摩尔,并且能刺激微管蛋白依赖性GTP水解,这与大多数其他秋水仙碱结合位点药物的情况相同。与秋水仙碱不同,库拉索霉素A与微管蛋白的结合类似于康普瑞他汀A - 4和鬼臼毒素的结合反应,因为它在冰上的结合程度与在较高温度下一样广泛。然而,一旦结合,库拉索霉素A从微管蛋白上的解离速率非常缓慢,与秋水仙碱类似物(所检测的药物是硫代秋水仙碱)的情况更相似,而不像康普瑞他汀A - 4和鬼臼毒素那样快速解离。由于库拉索霉素A的分子结构与先前描述的秋水仙碱结合位点药物有很大不同(例如,它没有芳香部分,并且其线性烃链中只有两个共轭双键),我们一直在研究天然异构体和合成衍生物的活性。到目前为止,通过各种结构变化仅观察到活性有适度的增强或降低。